Web of Science: 137 cites, Scopus: 153 cites, Google Scholar: cites,
Problems and challenges in the development and validation of human cell-based assays to determine nanoparticle-induced immunomodulatory effects
Oostingh, G. J. (Universität Salzburg. Fachbereich Molekulare Biologie)
Casals, Eudald (Institut Català de Nanociència i Nanotecnologia)
Italiani, Paola (Istituto Nanoscienze Consiglio Nazionale delle Ricerche. Istituto di Tecnologie Biomediche)
Colognato, Renato (Institute for Health and Consumer Protection (Ispra))
Stritzinger, René (Universität Salzburg. Fachbereich Molekulare Biologie)
Ponti, Jessica (Institute for Health and Consumer Protection (Ispra))
Pfaller, Tobias (Universität Salzburg. Fachbereich Molekulare Biologie)
Kohl, Yvonne (Fraunhofer-Institut für Biomedizinische Technik)
Ooms, Daniëla (Centre for Advanced R&D on Alternative Methods (Bèlgica))
Favilli, Flavia (Istituto Nanoscienze Consiglio Nazionale delle Ricerche. Istituto di Tecnologie Biomediche)
Leppens, Hilde (Centre for Advanced R&D on Alternative Methods (Bèlgica))
Lucchesi, Davide (Istituto Nanoscienze Consiglio Nazionale delle Ricerche. Istituto di Tecnologie Biomediche)
Rossi, François (Institute for Health and Consumer Protection (Ispra))
Nelissen, Inge (Centre for Advanced R&D on Alternative Methods (Bèlgica))
Thielecke, Hagen (Fraunhofer-Institut für Biomedizinische Technik)
Puntes, Víctor (Institució Catalana de Recerca i Estudis Avançats)
Duschl, Albert (Universität Salzburg. Fachbereich Molekulare Biologie)
Boraschi, Diana (Istituto Nanoscienze Consiglio Nazionale delle Ricerche. Istituto di Tecnologie Biomediche)

Data: 2011
Resum: Background: With the increasing use of nanomaterials, the need for methods and assays to examine their immunosafety is becoming urgent, in particular for nanomaterials that are deliberately administered to human subjects (as in the case of nanomedicines). To obtain reliable results, standardised in vitro immunotoxicological tests should be used to determine the effects of engineered nanoparticles on human immune responses. However, before assays can be standardised, it is important that suitable methods are established and validated. Results: In a collaborative work between European laboratories, existing immunological and toxicological in vitro assays were tested and compared for their suitability to test effects of nanoparticles on immune responses. The prototypical nanoparticles used were metal (oxide) particles, either custom-generated by wet synthesis or commercially available as powders. Several problems and challenges were encountered during assay validation, ranging from particle agglomeration in biological media and optical interference with assay systems, to chemical immunotoxicity of solvents and contamination with endotoxin. Conclusion: The problems that were encountered in the immunological assay systems used in this study, such as chemical or endotoxin contamination and optical interference caused by the dense material, significantly affected the data obtained. These problems have to be solved to enable the development of reliable assays for the assessment of nano-immunosafety.
Ajuts: European Commission 032131
Drets: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. Creative Commons
Llengua: Anglès
Document: Article ; recerca ; Versió publicada
Publicat a: Particle and fibre toxicology, Vol. 8 (February 2011) , art. 8, ISSN 1743-8977

DOI: 10.1186/1743-8977-8-8
PMID: 21306632

21 p, 792.0 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències > Institut Català de Nanociència i Nanotecnologia (ICN2)
Articles > Articles de recerca
Articles > Articles publicats

 Registre creat el 2019-06-03, darrera modificació el 2022-11-19

   Favorit i Compartir